All In Biotech

Drug Trial Radar · NCT05558007

Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients

Phase 2 Clinical Trial to Evaluate Safety and Efficacy of BZ371A in a Gel Applied in Patients That Performed Radical Prostatectomy

Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

72

Planned (sponsor's estimate)

Start

Nov 22, 2023

Primary completion

Dec 31, 2024

Study completion Jan 31, 2025

Sponsor

Lead sponsor
Biozeus Biopharmaceutical S.A.Industry
Sponsor type
Industry
First posted
Sep 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.

Conditions

  • Erectile Dysfunction Following Radical Prostatectomy
  • Erectile Dysfunction
  • Prostate Cancer
  • Radical Prostatectomy

Interventions

  • Tadalafil 5mgDrug

    Daily oral administration of tadalafil 5mg

  • BZ371ADrug

    Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL

  • Oral PlaceboDrug

    Oral administration of a placebo pill

  • Topical PlaceboDrug

    Topical application of 1.5 mL of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Assisted Erectile FunctionTime frame: From up to 30 days before Baseline, Baseline, 30 days, 60 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Urológica

    Belo Horizonte, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.